ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
$2.94 -0.01 (-0.34%)
As of 03/23/2023 15:59:58 EST IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Canada
Country of incorporation: Canada
IPO date: 11/15/2010
Outstanding shares: 162,570,989
Average volume: 1,217,282
Market cap: $464,953,029
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
Sedol: BZ0QMB7
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%